Larotrectinib (Lar) is a highly selective and potent small‐molecule inhibitor of all three tropomyosin receptor kinase (TRK) proteins, TRKA, TRKB and TRKC, in patients with TRK fusion‐positive cancer, including colon cancer.9 Here, NTRK1 is linked to colonic neoplasm.